Flucicovine F18 (FACBC) in Prostate Cancer - State of the Art Presentation

Cristina Nanni, MD. a leader in prostate cancer nuclear imaging, presents the data on Flucicovine F18 (FACBC), a new radiopharmaceutical and its application in diagnosisng biochemical replapse in post prostatectomy patients based upon a rising PSA.  Dr. Nanni also presents details on its mechanism of action in prostate cancer cells, the current clinical approach and reviews of patient case studies based on direct experiences in the devlopment of Flucicovine F18 (FACBC) . The discussion concludes with Dr. Phillip Koo leading a brief question and answer session on the practical applications of  Flucicovine F18. 


For More information of the use of F18 in the diagnosis of recurrent prostate cancer:

Hot Topic: Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer -

SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer

FDA Approval of Axumin™ (Flucicovine F18 (FACBC)

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.


Biography:


Cristina Nanni, MD.
Dr. Cristina Nanni is a Nuclear Medicine Physician working at the PET Centre in Bologna (ITALY) since 2007.

She got her residency in Nuclear Medicine at the University  Bologna (2000 to 2004) and in Radiology in 2012. She worked in the field of pre-clinical PET imaging in 2005 and 2006. Now she is responsible for new radiotracers applications and integration of morphological and functional imaging (PET/ceCT and PET/CT guided biopsy) in the clinical practice. 
Recently she is been working on the application of FACBC as an alternative tracer beside Choline in prostate cancer patients.
She is author and co-author of 190 clinical and pre-clinical papers published in international journals and more than 200 abstracts presented at national and international congresses as posters and oral presentations.

Phillip Koo, MD.
Division Chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, Gilbert, AZ

Dr. Koo is the Chief of Radiology at the Banner MD Anderson Cancer Center in Arizona.  Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine.  Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine.  
He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine.  Dr. Koo is an active member of multiple societies and serves on the scientific program committee for the Radiological Society of North America, nuclear radiology certifying exam committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging. 
In 2015, he was the recipient of the Ursula Mary Kocemba-Slosky Award from the SNMMI/ERF.  Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology and Journal of the American College of Radiology